Entvin AI is a startup founded by three IIT Bombay graduates that has been successful in raising its first round of funding. This round, which totaled USD 500,000, was led by Y Combinator.
The company specializes in providing artificial intelligence solutions to pharmaceutical and life sciences firms. It has plans to use the funds to expand the capabilities of its AI solutions and to accelerate customer acquisition, globally.
Solving Regulatory Challenges with AI
Entvin AI, started by Sanskar Jain, Hemant Phalak, and Rishabh Arya, takes on one of the top big thorns in the side of the pharmaceutical industry, the FDA drug approval process. This process is too often protracted, overstuffed with people and resources, and too complex to be anything but a rigorous obstacle course for those trying to bring a new drug to market. Too much depends on this process going in one direction for it to be anything other than a well-oiled machine.
Entvin AI has developed a platform to automate key regulatory workflows, which reduces inefficiencies and enhances compliance. Early enterprise pilot projects have shown the platform’s ability to save hundreds of hours for teams working on regulatory and scientific projects. Even better, the platform has the potential to save pharmaceutical companies millions of dollars in compliance costs.
How Entvin AI Works
The massive language models that Entvin AI employs are tailored for the realm of regulatory paperwork and are particularly well-suited for ensuring compliance with the rules laid down by the FDA. The platform they have constructed is capable of carrying out several important functions, most of which have traditionally been done manually. These include: automating the generation and organization of documents; carrying out comprehensive literature reviews; and flagging important changes in regulatory standards.
– Preparing regulatory documents
– Ensuring compliance with FDA regulations that are constantly changing
– Watching and interpreting the guidance coming from regulatory authorities on an as-it-happens basis
The platform aids life sciences firms in dealing with tough regulatory obligations by making these functions more efficient. You might say it’s like greasing the gears of a tough-running machine so that the machine does what it’s supposed to do, only it takes far fewer regulatory resources and far less time to get the desired outcomes with this platform.
Leadership Insights
Entvin AI Co-Founder and CEO, Sanskar Jain, calls for innovation in regulatory compliance. “Regulatory professionals spend countless hours handling documentation and compliance checks. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.”
In decision-making, AI plays a role, stressed Hemant Phalak, Co-Founder & CPO: “Our AI agents seamlessly integrate into existing workflows, not only organizing regulatory information but also identifying compliance gaps and providing actionable insights in real time.”
Rishabh Arya, Co-Founder & CTO, emphasized the platform’s technical sturdiness: “We have built an AI system capable of processing vast amounts of regulatory documentation while maintaining compliance with industry standards like SOC 2 and ISO 27001.”
With new funding from Y Combinator, Entvin AI aims to grow its capabilities and clientele among the mid-to-large global pharmaceutical companies. The startup wants to achieve something that its portfolio companies haven’t in the past: breaking into regulatory technology. Entvin AI sees itself as potentially helping life sciences firms to obtain drug approvals much more quickly and to do so while remaining compliant with a blizzard of rules.
